新华医疗
(600587)
| 流通市值：96.63亿 | | | 总市值：97.37亿 |
| 流通股本：6.02亿 | | | 总股本：6.07亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,423,276,804.99 | 5,186,552,479.09 | 2,528,538,840.43 | 10,011,868,423.4 |
| 营业收入 | 7,423,276,804.99 | 5,186,552,479.09 | 2,528,538,840.43 | 10,011,868,423.4 |
| 二、营业总成本 | 6,773,832,366.13 | 4,639,584,343.34 | 2,298,905,534.93 | 9,238,989,522.38 |
| 营业成本 | 5,469,945,360.84 | 3,804,148,405.05 | 1,904,427,546.66 | 7,271,306,435.97 |
| 税金及附加 | 50,843,853.06 | 36,187,188.6 | 14,318,968.54 | 76,988,683.09 |
| 销售费用 | 641,583,248.14 | 408,907,787.67 | 204,257,617.1 | 912,683,434.45 |
| 管理费用 | 301,150,902.47 | 197,507,985.46 | 88,190,919.48 | 520,242,394.01 |
| 研发费用 | 297,141,310.8 | 185,268,605.71 | 83,305,119.71 | 443,365,130.09 |
| 财务费用 | 13,167,690.82 | 7,564,370.85 | 4,405,363.44 | 14,403,444.77 |
| 其中:利息费用 | 33,851,006.57 | 22,736,938.57 | 13,623,404.33 | 47,071,823.36 |
| 其中:利息收入 | 20,692,553.27 | -15,348,988.4 | 7,969,683.01 | 29,846,241.93 |
| 加:公允价值变动收益 | - | - | - | 12,536,023.66 |
| 加:投资收益 | 52,663,544.58 | 39,215,747.98 | 18,623,683.78 | 81,117,962.39 |
| 资产处置收益 | 201,219.26 | 198,684.6 | 54,184.18 | 3,754,207.14 |
| 资产减值损失(新) | -10,341,512.28 | -13,052,323.6 | 1,488,567.34 | -47,477,564.31 |
| 信用减值损失(新) | -15,751,765.75 | -23,438,921.26 | -17,728,723.88 | -86,442,521.78 |
| 其他收益 | 50,225,227.23 | 15,624,494.71 | 6,273,998.64 | 20,586,374.43 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 726,441,151.9 | 565,515,818.18 | 238,345,015.56 | 756,953,382.55 |
| 加:营业外收入 | 4,200,855.35 | 3,437,620.86 | 1,959,729.57 | 10,584,775.84 |
| 减:营业外支出 | 6,561,548.89 | 1,479,791.25 | 300,014.46 | 28,959,031.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 724,080,458.36 | 567,473,647.79 | 240,004,730.67 | 738,579,127.23 |
| 减:所得税费用 | 90,127,083.71 | 69,414,305.47 | 24,980,580.65 | 62,077,744.01 |
| 六、净利润 | 633,953,374.65 | 498,059,342.32 | 215,024,150.02 | 676,501,383.22 |
| 持续经营净利润 | 633,953,374.65 | 498,059,342.32 | 215,024,150.02 | 676,501,383.22 |
| 归属于母公司股东的净利润 | 617,001,476.94 | 484,262,168.63 | 211,036,820.12 | 653,997,275.95 |
| 少数股东损益 | 16,951,897.71 | 13,797,173.69 | 3,987,329.9 | 22,504,107.27 |
| (一)基本每股收益 | 1.17 | 0.99 | 0.45 | 1.43 |
| (二)稀释每股收益 | 1.17 | 0.99 | 0.45 | 1.43 |
| 八、其他综合收益 | 62,894.13 | 62,894.13 | - | 21,899 |
| 归属于母公司股东的其他综合收益 | 62,894.13 | 62,894.13 | - | 21,899 |
| 九、综合收益总额 | 634,016,268.78 | 498,122,236.45 | 215,024,150.02 | 676,523,282.22 |
| 归属于母公司股东的综合收益总额 | 617,064,371.07 | 484,325,062.76 | 211,036,820.12 | 654,019,174.95 |
| 归属于少数股东的综合收益总额 | 16,951,897.71 | 13,797,173.69 | 3,987,329.9 | 22,504,107.27 |
| 公告日期 | 2024-10-30 | 2024-08-30 | 2024-04-30 | 2024-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |